1. Pink Sheet

Pazdurcanumab: US FDA’s Top Cancer Official Weighs In On That Big Neurology Approval

 
• By Kate Rawson

Richard Pazdur is eager for a conversation about how to improve the Accelerated Approval pathway. The OCE director welcomes aducanumab’s approval – both on its own terms but also as an opportunity to broaden the discussion.

OCE Director Richard Pazdur is part of the US FDA's brain trust on accelerated approval • Source: photo illustration/Alamy, FDA

The US Food & Drug Administration’s top oncology review manager has a lot to say about the agency’s biggest neurological drug approval in decades.

During a 8 June

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards